SILA | Ticker Profile - Titan Protect

SILA

Sila Realty Trust, Inc.

Real Estate · REIT - Healthcare Facilities · NYQ

$30.25

Data: 2026-05-28

✓ ETHICAL PASS

Unknown MOAT

HIGH

Data Confidence: 85.7%

Key Metrics

How this company measures up on the fundamentals that matter

Market Cap

$1.7B

Total market value of the company

Trailing P/E

44.50

Expensive — high growth expected

Forward P/E

N/A

Based on estimated future earnings — lower means cheaper

Rev Growth

+9.1%

Year-over-year revenue change

Profit Margin

18.6%

How much profit the company keeps from each dollar of revenue

ROE

2.8%

Return on equity — how efficiently it uses shareholder money

Analyst Target

$30.00

-1% from current price — median analyst estimate

Recommendation

HOLD

Consensus view from 4 analysts covering this stock

About Sila Realty Trust, Inc.

Sila Realty Trust, Inc. is a net lease real estate investment trust with a strategic focus on investing in the growing and resilient healthcare sector. The Company invests in high quality healthcare facilities along the continuum of care in the pursuit of generating predictable, durable, and growing income streams. Sila's portfolio comprises high quality tenants in geographically diverse facilities, which are positioned to capitalize on the dynamic delivery of healthcare to patients. As of March 31, 2026, the Company owned 137 real estate properties and three undeveloped land parcels, located in 65 markets across the United States. Sila Realty Trust, Inc. is organized as Maryland corporation in 2013 and headquarters in Tampa, Florida.

https://silarealtytrust.com

Country: United States Employees: 47 Industry: REIT - Healthcare Facilities

Ethical Screening

Five compliance checks based on AAOIFI standards — all must pass for ethical clearance

Business Activity

PASS

Core business does not involve prohibited activities

Debt Ratio

0.0% N/A

Debt must be below 33% of total assets

Cash Ratio

0.0% N/A

Interest-bearing cash below 33% of assets

Receivables

0.0% N/A

Receivables below 49% of assets

Revenue Purity

0.0% PASS

Non-compliant revenue below 5% — any excess requires purification

Quantitative Intelligence

Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data

Regime

ACCUMULATION

Smart money appears to be building positions quietly

Sharpe Ratio

0.927

Good returns relative to risk taken

Kelly Fraction

0.0538

Suggested allocation is meaningful — the edge justifies a position

Calmar Ratio

1.581

Returns exceed worst-case losses — strong risk profile

Annual Return

23.7%

Historical annualised return based on price data

Max Drawdown

-15.0%

Largest peak-to-trough decline — the worst it has been

HMM State

SIDEWAYS

Price consolidating — no clear directional bias

Days in State

How long the current regime has persisted — longer means more stable

Market Data

Trading characteristics and market positioning

Beta

0.33

Very low correlation to market moves

52W High

$30.63

1% below the year high

52W Low

$21.94

38% above the year low

Avg Volume

733,998

Average daily shares traded — higher means easier to buy and sell

Short Ratio

0.4

Days it would take all short sellers to cover — higher means more crowded

Short % Float

1.1%

Low short interest — limited bearish positioning

Div Yield

529.0%

Annual dividend as a percentage of the share price

EPS (TTM)

$0.68

Earnings per share over the last 12 months

Financial Health

Balance sheet strength and cash generation — the foundation of long-term value

Debt/Equity

55.17

Heavy leverage — higher financial risk if revenues decline

Current Ratio

6.52

Strong balance sheet — comfortably covers short-term obligations

Quick Ratio

6.36

Like current ratio but excludes inventory — stricter test

Gross Margin

88.3%

Revenue left after cost of goods — higher means pricing power

Operating Margin

41.2%

Profit from core operations before interest and tax

Free Cash Flow

$93M

Positive — the business generates more cash than it spends

Revenue (TTM)

$202M

Total revenue over the last 12 months

Net Income

$37M

Profitable — the bottom line is positive

Analyst Coverage

Analysts

Target High

$31.00

Target Median

$30.00

Target Low

$28.00

Explore the Ethical Screener View Track Record

Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-05-28

Before you go